In our study, we first found that H-UDCA/RSV/EZE treatment decreased serum ALT levels and mRNA levels of fibrosis-related factors compared to L-UDCA/RSV/EZE treatment in TAA-induced liver fibrosis. This evidence concerns the gene GPT and Hepatic fibrosis.